ST. LOUIS, Feb. 8 /PRNewswire/ -- Mallinckrodt Inc. (NYSE: MKG), an
established leader in contrast media, sold its first Liebel-Flarsheim brand
Optistar(TM) MR contrast power injectors in the United States in January,
following the U.S. Food and Drug Administration's (FDA) December 1999
clearance for the company to market the device. The product is also being
sold in Canada. Power injectors are used to introduce contrast media into the
body in a controlled manner.
"We're extremely excited about the Optistar power injector," said Bradley
J. Fercho, president of Mallinckrodt's Imaging Group. "Its wide variety of
beneficial options will make it a valuable addition to MRI labs around the
country.
"The fact that our first sale in the rapidly growing MR injector market
was to Washington University's prestigious Mallinckrodt Institute of Radiology
in St. Louis is a solid commentary on Optistar's quality. This product is
another indication of Mallinckrodt's commitment to being a single-source
supplier for the contrast imaging market."
The Optistar MR contrast delivery system provides fast, easy and versatile
contrast delivery to facilitate simple and efficient dynamic magnetic
resonance imaging (MRI) procedures. Among the options available with Optistar
are:
-- A quick and easy loading system for empty or prefilled syringes.
-- The ability to preprogram options, creating faster procedures and
customized parameters for each patient.
-- Responsive touch-screen controls to quickly set the amount of contrast
or saline and the rate of injection.
-- The ability to switch from injection to drip mode at any time, thereby
ensuring patency.
-- A convenient battery and charger pack to power the system.
-- A multicolored LED screen that makes all elements easy to read, even
from wide angles.
-- Start and stop controls that can be operated either from a central
console or at the patient's side.
Mallinckrodt estimates the market for power injectors to be in the range
of $35 million a year.
Based in St. Louis, Missouri, Mallinckrodt Inc. is a global manufacturer
and marketer of specialty medical products designed to sustain breathing,
diagnose disease, and relieve pain. The company does business in more than
100 countries, operates Respiratory, Imaging and Pharmaceuticals product
groups and had fiscal 1999 net sales of $2.6 billion. The Imaging Group
specializes in contrast media for x-ray, ultrasound and MRI procedures, and
radiopharmaceutical imaging used to diagnose and treat disease. The
Mallinckrodt website address is http://www.mallinckrodt.com .
For electronic (.tif) photo: E-mail: brenda.spencer@mkg.com.
SOURCE Mallinckrodt Inc.
 back to top
Related links:
http://www.mallinckrodt.com
Company News On-Call:
http://www.prnewswire.com/comp/440950.html or fax,
800-758-5804, ext. 440950
CONTACT:
Media, Barbara Abbett, 314-654-5230, or
barbara.abbett@mkg.com, or Investors, Barbara Gould,
314-654-3190, or Invest@mkg.com, both of Mallinckrodt Inc.
|
